Methylmalonic and propionic acidurias: Management without or with a few supplements of specific amino acid mixture

Summary In a series of 137 patients with methylmalonic acidaemia (MMA) and propionic acidaemia (PA) diagnosed since the early 1970s, we report in more detail 81 patients (51 MMA and 30 PA) diagnosed between 1988 and 2005. In this series, 14% of patients died at initial access revealing the disease b...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of inherited metabolic disease 2006-04, Vol.29 (2-3), p.288-298
Hauptverfasser: Touati, G., Valayannopoulos, V., Mention, K., Lonlay, P., Jouvet, P., Depondt, E., Assoun, M., Souberbielle, J. C., Rabier, D., Ogier de Baulny, H., Saudubray, J.‐M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 298
container_issue 2-3
container_start_page 288
container_title Journal of inherited metabolic disease
container_volume 29
creator Touati, G.
Valayannopoulos, V.
Mention, K.
Lonlay, P.
Jouvet, P.
Depondt, E.
Assoun, M.
Souberbielle, J. C.
Rabier, D.
Ogier de Baulny, H.
Saudubray, J.‐M.
description Summary In a series of 137 patients with methylmalonic acidaemia (MMA) and propionic acidaemia (PA) diagnosed since the early 1970s, we report in more detail 81 patients (51 MMA and 30 PA) diagnosed between 1988 and 2005. In this series, 14% of patients died at initial access revealing the disease before or despite treatment, 18% died later, and the remainder (68%) are still alive. All patients were treated with the same protocol of enteral feeds with a low‐protein diet adjusted to individual tolerance, carnitine, antibiotics, and only occasional use of an amino acid (AA) mixture. There was intensive follow‐up and monitoring using measurements of urinary urea. Thirty‐nine patients with severe forms, followed for more than 3 years, are analysed in particular detail. Of the 17 PA patients, 6 had moderate disability (all neonatal‐onset forms), whereas 11 were normal or slightly delayed in their mental development. Four presented with cardiomyopathy, of whom 2 died. Of the 22 MMA patients, 13 presented in the neonatal period, of whom 3 died later, 2 are in renal failure and only 5 are still alive and have a normal or slightly delayed mental development. In the 9 patients with late‐onset forms, there were no deaths and all patients but one have normal mental development. Among the 39 patients, only 40% were given an AA supplement at 3 years, and 50% between 6 and 11 years. The actual intake of natural protein was 0.92, 0.78 and 0.77 g/kg per day at 3, 6 and 11 years, respectively, in patients without AA supplementation, whereas it was 0.75, 0.74 and 0.54 g/kg per day in the group who received small quantities of AA (0.4–0.6 g/kg per day). In both groups, feeding disorders were frequent: 55% at 3 years, 35% at 6 years and 12% at 11 years. Many patients were given a food supplement by tube overnight or were even exclusively tube fed: 60% at 3 years, 48% at 6 years and still 27% at 11 years. Growth velocity was near the normal values. Plasma valine and isoleucine were low to very low, as were leucine and phenylalanine but to a lesser extent. Albumin, vitamins, trace elements and markers of bone metabolism were within the normal values. IGF1, 24‐hour urine calcium and body mass density were low. Body composition showed a normal to low lean mass and a normal to high fat mass.
doi_str_mv 10.1007/s10545-006-0351-7
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68057670</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68057670</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4178-58758d59286300860b650fb9f6b2fc8ad29b9d346a92021df0b39dc1aef93f513</originalsourceid><addsrcrecordid>eNqFkc1O3DAUha2qVRmgD9ANsrroLvTajv_YVVB-KkZs6NpyErsYJXGwE03n7clMRkLqhtX1lb7zyfZB6CuBcwIgf2QCvOQFgCiAcVLID2hFuGQFFYJ_RCsgJSmU5vwIHef8DABacf4ZHREhBVMaViit3fi0bTvbxj7U2PYNHlIcwrLVoZlSsPkCr21v_7rO9SPehPEpTiOOaX_EFnu3wXkahnYPZBw9zoOrg985utDHvQl34d84JXeKPnnbZvflME_Qn-tfj5e3xf3Dzd3lz_uiLolUBVeSq4ZrqgQDUAIqwcFX2ouK-lrZhupKN6wUVlOgpPFQMd3UxDqvmeeEnaDvi3d-0Mvk8mi6kGvXtrZ3ccpGKOBSSJjBb_-Bz3FK_Xw3Q4lSpSxLOkNkgeoUc07OmyGFzqatIWB2bZilDTO3YXZtGDlnzg7iqepc85Y4fP8MyAXYhNZt3zea33frK6BKsVfHfpZS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218847442</pqid></control><display><type>article</type><title>Methylmalonic and propionic acidurias: Management without or with a few supplements of specific amino acid mixture</title><source>MEDLINE</source><source>SpringerNature Journals</source><source>Access via Wiley Online Library</source><creator>Touati, G. ; Valayannopoulos, V. ; Mention, K. ; Lonlay, P. ; Jouvet, P. ; Depondt, E. ; Assoun, M. ; Souberbielle, J. C. ; Rabier, D. ; Ogier de Baulny, H. ; Saudubray, J.‐M.</creator><creatorcontrib>Touati, G. ; Valayannopoulos, V. ; Mention, K. ; Lonlay, P. ; Jouvet, P. ; Depondt, E. ; Assoun, M. ; Souberbielle, J. C. ; Rabier, D. ; Ogier de Baulny, H. ; Saudubray, J.‐M.</creatorcontrib><description>Summary In a series of 137 patients with methylmalonic acidaemia (MMA) and propionic acidaemia (PA) diagnosed since the early 1970s, we report in more detail 81 patients (51 MMA and 30 PA) diagnosed between 1988 and 2005. In this series, 14% of patients died at initial access revealing the disease before or despite treatment, 18% died later, and the remainder (68%) are still alive. All patients were treated with the same protocol of enteral feeds with a low‐protein diet adjusted to individual tolerance, carnitine, antibiotics, and only occasional use of an amino acid (AA) mixture. There was intensive follow‐up and monitoring using measurements of urinary urea. Thirty‐nine patients with severe forms, followed for more than 3 years, are analysed in particular detail. Of the 17 PA patients, 6 had moderate disability (all neonatal‐onset forms), whereas 11 were normal or slightly delayed in their mental development. Four presented with cardiomyopathy, of whom 2 died. Of the 22 MMA patients, 13 presented in the neonatal period, of whom 3 died later, 2 are in renal failure and only 5 are still alive and have a normal or slightly delayed mental development. In the 9 patients with late‐onset forms, there were no deaths and all patients but one have normal mental development. Among the 39 patients, only 40% were given an AA supplement at 3 years, and 50% between 6 and 11 years. The actual intake of natural protein was 0.92, 0.78 and 0.77 g/kg per day at 3, 6 and 11 years, respectively, in patients without AA supplementation, whereas it was 0.75, 0.74 and 0.54 g/kg per day in the group who received small quantities of AA (0.4–0.6 g/kg per day). In both groups, feeding disorders were frequent: 55% at 3 years, 35% at 6 years and 12% at 11 years. Many patients were given a food supplement by tube overnight or were even exclusively tube fed: 60% at 3 years, 48% at 6 years and still 27% at 11 years. Growth velocity was near the normal values. Plasma valine and isoleucine were low to very low, as were leucine and phenylalanine but to a lesser extent. Albumin, vitamins, trace elements and markers of bone metabolism were within the normal values. IGF1, 24‐hour urine calcium and body mass density were low. Body composition showed a normal to low lean mass and a normal to high fat mass.</description><identifier>ISSN: 0141-8955</identifier><identifier>EISSN: 1573-2665</identifier><identifier>DOI: 10.1007/s10545-006-0351-7</identifier><identifier>PMID: 16763890</identifier><language>eng</language><publisher>Dordrecht: Kluwer Academic Publishers</publisher><subject>Amino Acid Metabolism, Inborn Errors - diet therapy ; Amino Acid Metabolism, Inborn Errors - drug therapy ; Amino Acid Metabolism, Inborn Errors - therapy ; Amino Acid Metabolism, Inborn Errors - urine ; Amino Acids - blood ; Amino Acids - therapeutic use ; Body Height ; Body Weight ; Chemistry, Pharmaceutical ; Child ; Child, Preschool ; Diet, Protein-Restricted ; Dietary Proteins - metabolism ; Dietary Supplements ; Eating ; Enteral Nutrition ; Female ; Follow-Up Studies ; Hospitalization ; Humans ; Lactic Acid - analogs &amp; derivatives ; Lactic Acid - urine ; Male ; Methylmalonic Acid - urine ; Nutrition Assessment ; Propionates - urine ; Treatment Outcome</subject><ispartof>Journal of inherited metabolic disease, 2006-04, Vol.29 (2-3), p.288-298</ispartof><rights>2006 SSIEM</rights><rights>SSIEM and Springer 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4178-58758d59286300860b650fb9f6b2fc8ad29b9d346a92021df0b39dc1aef93f513</citedby><cites>FETCH-LOGICAL-c4178-58758d59286300860b650fb9f6b2fc8ad29b9d346a92021df0b39dc1aef93f513</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1007%2Fs10545-006-0351-7$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1007%2Fs10545-006-0351-7$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16763890$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Touati, G.</creatorcontrib><creatorcontrib>Valayannopoulos, V.</creatorcontrib><creatorcontrib>Mention, K.</creatorcontrib><creatorcontrib>Lonlay, P.</creatorcontrib><creatorcontrib>Jouvet, P.</creatorcontrib><creatorcontrib>Depondt, E.</creatorcontrib><creatorcontrib>Assoun, M.</creatorcontrib><creatorcontrib>Souberbielle, J. C.</creatorcontrib><creatorcontrib>Rabier, D.</creatorcontrib><creatorcontrib>Ogier de Baulny, H.</creatorcontrib><creatorcontrib>Saudubray, J.‐M.</creatorcontrib><title>Methylmalonic and propionic acidurias: Management without or with a few supplements of specific amino acid mixture</title><title>Journal of inherited metabolic disease</title><addtitle>J Inherit Metab Dis</addtitle><description>Summary In a series of 137 patients with methylmalonic acidaemia (MMA) and propionic acidaemia (PA) diagnosed since the early 1970s, we report in more detail 81 patients (51 MMA and 30 PA) diagnosed between 1988 and 2005. In this series, 14% of patients died at initial access revealing the disease before or despite treatment, 18% died later, and the remainder (68%) are still alive. All patients were treated with the same protocol of enteral feeds with a low‐protein diet adjusted to individual tolerance, carnitine, antibiotics, and only occasional use of an amino acid (AA) mixture. There was intensive follow‐up and monitoring using measurements of urinary urea. Thirty‐nine patients with severe forms, followed for more than 3 years, are analysed in particular detail. Of the 17 PA patients, 6 had moderate disability (all neonatal‐onset forms), whereas 11 were normal or slightly delayed in their mental development. Four presented with cardiomyopathy, of whom 2 died. Of the 22 MMA patients, 13 presented in the neonatal period, of whom 3 died later, 2 are in renal failure and only 5 are still alive and have a normal or slightly delayed mental development. In the 9 patients with late‐onset forms, there were no deaths and all patients but one have normal mental development. Among the 39 patients, only 40% were given an AA supplement at 3 years, and 50% between 6 and 11 years. The actual intake of natural protein was 0.92, 0.78 and 0.77 g/kg per day at 3, 6 and 11 years, respectively, in patients without AA supplementation, whereas it was 0.75, 0.74 and 0.54 g/kg per day in the group who received small quantities of AA (0.4–0.6 g/kg per day). In both groups, feeding disorders were frequent: 55% at 3 years, 35% at 6 years and 12% at 11 years. Many patients were given a food supplement by tube overnight or were even exclusively tube fed: 60% at 3 years, 48% at 6 years and still 27% at 11 years. Growth velocity was near the normal values. Plasma valine and isoleucine were low to very low, as were leucine and phenylalanine but to a lesser extent. Albumin, vitamins, trace elements and markers of bone metabolism were within the normal values. IGF1, 24‐hour urine calcium and body mass density were low. Body composition showed a normal to low lean mass and a normal to high fat mass.</description><subject>Amino Acid Metabolism, Inborn Errors - diet therapy</subject><subject>Amino Acid Metabolism, Inborn Errors - drug therapy</subject><subject>Amino Acid Metabolism, Inborn Errors - therapy</subject><subject>Amino Acid Metabolism, Inborn Errors - urine</subject><subject>Amino Acids - blood</subject><subject>Amino Acids - therapeutic use</subject><subject>Body Height</subject><subject>Body Weight</subject><subject>Chemistry, Pharmaceutical</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Diet, Protein-Restricted</subject><subject>Dietary Proteins - metabolism</subject><subject>Dietary Supplements</subject><subject>Eating</subject><subject>Enteral Nutrition</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Lactic Acid - analogs &amp; derivatives</subject><subject>Lactic Acid - urine</subject><subject>Male</subject><subject>Methylmalonic Acid - urine</subject><subject>Nutrition Assessment</subject><subject>Propionates - urine</subject><subject>Treatment Outcome</subject><issn>0141-8955</issn><issn>1573-2665</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkc1O3DAUha2qVRmgD9ANsrroLvTajv_YVVB-KkZs6NpyErsYJXGwE03n7clMRkLqhtX1lb7zyfZB6CuBcwIgf2QCvOQFgCiAcVLID2hFuGQFFYJ_RCsgJSmU5vwIHef8DABacf4ZHREhBVMaViit3fi0bTvbxj7U2PYNHlIcwrLVoZlSsPkCr21v_7rO9SPehPEpTiOOaX_EFnu3wXkahnYPZBw9zoOrg985utDHvQl34d84JXeKPnnbZvflME_Qn-tfj5e3xf3Dzd3lz_uiLolUBVeSq4ZrqgQDUAIqwcFX2ouK-lrZhupKN6wUVlOgpPFQMd3UxDqvmeeEnaDvi3d-0Mvk8mi6kGvXtrZ3ccpGKOBSSJjBb_-Bz3FK_Xw3Q4lSpSxLOkNkgeoUc07OmyGFzqatIWB2bZilDTO3YXZtGDlnzg7iqepc85Y4fP8MyAXYhNZt3zea33frK6BKsVfHfpZS</recordid><startdate>200604</startdate><enddate>200604</enddate><creator>Touati, G.</creator><creator>Valayannopoulos, V.</creator><creator>Mention, K.</creator><creator>Lonlay, P.</creator><creator>Jouvet, P.</creator><creator>Depondt, E.</creator><creator>Assoun, M.</creator><creator>Souberbielle, J. C.</creator><creator>Rabier, D.</creator><creator>Ogier de Baulny, H.</creator><creator>Saudubray, J.‐M.</creator><general>Kluwer Academic Publishers</general><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>200604</creationdate><title>Methylmalonic and propionic acidurias: Management without or with a few supplements of specific amino acid mixture</title><author>Touati, G. ; Valayannopoulos, V. ; Mention, K. ; Lonlay, P. ; Jouvet, P. ; Depondt, E. ; Assoun, M. ; Souberbielle, J. C. ; Rabier, D. ; Ogier de Baulny, H. ; Saudubray, J.‐M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4178-58758d59286300860b650fb9f6b2fc8ad29b9d346a92021df0b39dc1aef93f513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Amino Acid Metabolism, Inborn Errors - diet therapy</topic><topic>Amino Acid Metabolism, Inborn Errors - drug therapy</topic><topic>Amino Acid Metabolism, Inborn Errors - therapy</topic><topic>Amino Acid Metabolism, Inborn Errors - urine</topic><topic>Amino Acids - blood</topic><topic>Amino Acids - therapeutic use</topic><topic>Body Height</topic><topic>Body Weight</topic><topic>Chemistry, Pharmaceutical</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Diet, Protein-Restricted</topic><topic>Dietary Proteins - metabolism</topic><topic>Dietary Supplements</topic><topic>Eating</topic><topic>Enteral Nutrition</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Lactic Acid - analogs &amp; derivatives</topic><topic>Lactic Acid - urine</topic><topic>Male</topic><topic>Methylmalonic Acid - urine</topic><topic>Nutrition Assessment</topic><topic>Propionates - urine</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Touati, G.</creatorcontrib><creatorcontrib>Valayannopoulos, V.</creatorcontrib><creatorcontrib>Mention, K.</creatorcontrib><creatorcontrib>Lonlay, P.</creatorcontrib><creatorcontrib>Jouvet, P.</creatorcontrib><creatorcontrib>Depondt, E.</creatorcontrib><creatorcontrib>Assoun, M.</creatorcontrib><creatorcontrib>Souberbielle, J. C.</creatorcontrib><creatorcontrib>Rabier, D.</creatorcontrib><creatorcontrib>Ogier de Baulny, H.</creatorcontrib><creatorcontrib>Saudubray, J.‐M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of inherited metabolic disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Touati, G.</au><au>Valayannopoulos, V.</au><au>Mention, K.</au><au>Lonlay, P.</au><au>Jouvet, P.</au><au>Depondt, E.</au><au>Assoun, M.</au><au>Souberbielle, J. C.</au><au>Rabier, D.</au><au>Ogier de Baulny, H.</au><au>Saudubray, J.‐M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Methylmalonic and propionic acidurias: Management without or with a few supplements of specific amino acid mixture</atitle><jtitle>Journal of inherited metabolic disease</jtitle><addtitle>J Inherit Metab Dis</addtitle><date>2006-04</date><risdate>2006</risdate><volume>29</volume><issue>2-3</issue><spage>288</spage><epage>298</epage><pages>288-298</pages><issn>0141-8955</issn><eissn>1573-2665</eissn><abstract>Summary In a series of 137 patients with methylmalonic acidaemia (MMA) and propionic acidaemia (PA) diagnosed since the early 1970s, we report in more detail 81 patients (51 MMA and 30 PA) diagnosed between 1988 and 2005. In this series, 14% of patients died at initial access revealing the disease before or despite treatment, 18% died later, and the remainder (68%) are still alive. All patients were treated with the same protocol of enteral feeds with a low‐protein diet adjusted to individual tolerance, carnitine, antibiotics, and only occasional use of an amino acid (AA) mixture. There was intensive follow‐up and monitoring using measurements of urinary urea. Thirty‐nine patients with severe forms, followed for more than 3 years, are analysed in particular detail. Of the 17 PA patients, 6 had moderate disability (all neonatal‐onset forms), whereas 11 were normal or slightly delayed in their mental development. Four presented with cardiomyopathy, of whom 2 died. Of the 22 MMA patients, 13 presented in the neonatal period, of whom 3 died later, 2 are in renal failure and only 5 are still alive and have a normal or slightly delayed mental development. In the 9 patients with late‐onset forms, there were no deaths and all patients but one have normal mental development. Among the 39 patients, only 40% were given an AA supplement at 3 years, and 50% between 6 and 11 years. The actual intake of natural protein was 0.92, 0.78 and 0.77 g/kg per day at 3, 6 and 11 years, respectively, in patients without AA supplementation, whereas it was 0.75, 0.74 and 0.54 g/kg per day in the group who received small quantities of AA (0.4–0.6 g/kg per day). In both groups, feeding disorders were frequent: 55% at 3 years, 35% at 6 years and 12% at 11 years. Many patients were given a food supplement by tube overnight or were even exclusively tube fed: 60% at 3 years, 48% at 6 years and still 27% at 11 years. Growth velocity was near the normal values. Plasma valine and isoleucine were low to very low, as were leucine and phenylalanine but to a lesser extent. Albumin, vitamins, trace elements and markers of bone metabolism were within the normal values. IGF1, 24‐hour urine calcium and body mass density were low. Body composition showed a normal to low lean mass and a normal to high fat mass.</abstract><cop>Dordrecht</cop><pub>Kluwer Academic Publishers</pub><pmid>16763890</pmid><doi>10.1007/s10545-006-0351-7</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0141-8955
ispartof Journal of inherited metabolic disease, 2006-04, Vol.29 (2-3), p.288-298
issn 0141-8955
1573-2665
language eng
recordid cdi_proquest_miscellaneous_68057670
source MEDLINE; SpringerNature Journals; Access via Wiley Online Library
subjects Amino Acid Metabolism, Inborn Errors - diet therapy
Amino Acid Metabolism, Inborn Errors - drug therapy
Amino Acid Metabolism, Inborn Errors - therapy
Amino Acid Metabolism, Inborn Errors - urine
Amino Acids - blood
Amino Acids - therapeutic use
Body Height
Body Weight
Chemistry, Pharmaceutical
Child
Child, Preschool
Diet, Protein-Restricted
Dietary Proteins - metabolism
Dietary Supplements
Eating
Enteral Nutrition
Female
Follow-Up Studies
Hospitalization
Humans
Lactic Acid - analogs & derivatives
Lactic Acid - urine
Male
Methylmalonic Acid - urine
Nutrition Assessment
Propionates - urine
Treatment Outcome
title Methylmalonic and propionic acidurias: Management without or with a few supplements of specific amino acid mixture
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T13%3A09%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Methylmalonic%20and%20propionic%20acidurias:%20Management%20without%20or%20with%20a%20few%20supplements%20of%20specific%20amino%20acid%20mixture&rft.jtitle=Journal%20of%20inherited%20metabolic%20disease&rft.au=Touati,%20G.&rft.date=2006-04&rft.volume=29&rft.issue=2-3&rft.spage=288&rft.epage=298&rft.pages=288-298&rft.issn=0141-8955&rft.eissn=1573-2665&rft_id=info:doi/10.1007/s10545-006-0351-7&rft_dat=%3Cproquest_cross%3E68057670%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218847442&rft_id=info:pmid/16763890&rfr_iscdi=true